

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonistin lung cancer, you should report all associations with entities pursuing diagnostic or the rapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

5.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming into you or your institution due to your

patent



Section 1. Identifying Info	ormation	
1. Given Name (First Name)	2. Surname (LastName)	3. Date 3/27/20 ·
4. Are you the corresponding author?	Yes No	, ,
5. Manuscript Title Augusto mi	cal Robohz Propate	clony: feehoural factors
6. Manuscript Identifying Number (if yo	u know it) AU-19-564).	to achieve super continuand erechle function
Section 2. The Work Unde	er Consideration for Publicatio	n
Did you or your institution at any time reany aspect of the submitted work (inclustratistical analysis, etc.)? Are there any relevant conflicts of	uding but not limited to grants, data mor	ty (government, commercial, private foundation, etc.) for nitoring board, study design, manuscript preparation,
Section 3. Relevant finance	cial activities outside the subn	nitted work.
-fdention) with antitios as de	scribed in the instructions. Use one in I report relationships that were prese	have financial relationships (regardless of amount the for each entity; add as many lines as you need by nt during the 36 months prior to publication.
Section 4. Intellectual Pro	operty Patents & Copyrights	
Intenectual Fro	sperty Patents & Copyrights	levantto the work? Yes No



Section 5.	Relationships not covered above			
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?				
Yes the foll	owing relationships/conditions/circumstances are present (explain below):			
to other relationships/conditions/circumstances that present a potential conflict of interest				
Atthetimeofma On occasion, jo	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. urnals may ask authors to disclose further information about reported relationships.			
Section 6.	Disclosure Statement			
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.				
Generate Dis	sclosure Statement			
No	COIS			

Evaluati in and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

3/2-120



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	nation			
1. Given Name (First Name) Ashutosh	2. Surname (Last Name) Tewari	3. Date 19-March-2020		
4. Are you the corresponding author?	✓ Yes No			
5. Manuscript Title Anatomical Robotic Prostatectomy: Technical Factors to Achieve Superb Continence and Erectile Function				
6. Manuscript Identifying Number (if you know it) TAU-2019-RAUS-13(TAU-19-564)				
Section 2. The Work Under C	onsideration for Publication			
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?				
Are there any relevant conflicts of interest? Yes Vo				
Section 3. Relevant financial	activities outside the submitted work.			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication .				
Are there any relevant conflicts of interest? Yes Vo				
Section 4. Intellectual Proper	rty Patents & Copyrights			
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo				



Section 5.

Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

No other relationships/conditions/circumstances that present a potential conflict of interest

CONFLICTS OF INTEREST

Dr. Ash Tewari as of 2020

COMPANY RELATIONSHIP TYPE FINANCIAL

Uretheral Catheterless Radical Prostatectomy Patent No

DNA Based Bicistronic Vectors with Inducible and Constitutive Promoters - ID#: 160608 Patent No

High Intensity Focus Ultrasound and CPG-BrachyurysiRNA for Treatment of Prostate Cancer - ID# 160403 Patent No

Patent for a Catheterless Device and Approach Patent No

*Promaxo Leadership Position Yes

*Promaxo Equity Ownership YES

Global Prostate Cancer Research Foundation Leadership Position No

Kalyani Prostate Cancer Institute Leadership Position No

Prostate Cancer Foundation Leadership Position No

Roivant Consultant No

Blank Family Foundation Grant Yes

Intuitive Surgical Scientific Study or Trial Yes

Department of Defense (DOD) Scientific Study or Trial Yes

AxoGen, Inc. Scientific Study or Trial Yes

Oncovir, Inc - Poly ICLC Scientific Study or Trial Yes

National Institute of Health (NIH/DHHS) Scientific Study or Trial Yes

National Cancer Institute Scientific Study or Trial Yes

National Institute on Drug Abuse Scientific Study or Trial Yes

Kite Pharma Scientific Study or Trial Yes

Lumicell, Inc Scientific Study or Trial Yes

Dendreon Scientific Study or Trial Yes

*PROMAXO: Common Stock Certificate VALUE: 51,205 % SHARE RELATED PARTY: 0.63

- Intuitive no salary/ see referenced COI's
- Promaxo no salary/investment see referenced COI's
- Kite Pharma: Serve as PI. Industry funded for research procedures. Site PI performance no salary
- Poly ICLC: Serve as site PI. Phase I Study of IN SITU Autologous Vaccination Against Prostate Cancer With Intratumoral and Systemic HILTONOL (POLY-ICLC) Prior to Radical Prostatectomy. Product provided free of charge no other funding. -- No salary

*Dr. Ash Tewari (the Principal Investigator in this study and Chairman of Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai) owns equity in the form of stock certificates in Promaxo, for which he serves as an advisor. Promaxo is a privately traded company which develops MRI technology with a focus on prostate cancer.

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Tewari reports and CONFLICTS OF INTEREST

Dr. Ash Tewari

as of 2020

COMPANY RELATIONSHIP TYPE FINANCIAL

Uretheral Catheterless Radical Prostatectomy Patent No

DNA Based Bicistronic Vectors with Inducible and Constitutive Promoters - ID#: 160608 Patent No

High Intensity Focus Ultrasound and CPG-BrachyurysiRNA for Treatment of Prostate Cancer - ID# 160403 Patent No

Patent for a Catheterless Device and Approach Patent No

*Promaxo Leadership Position Yes

*Promaxo Equity Ownership YES

Global Prostate Cancer Research Foundation Leadership Position No

Kalyani Prostate Cancer Institute Leadership Position No

Prostate Cancer Foundation Leadership Position No

Roivant Consultant No

Blank Family Foundation Grant Yes

Intuitive Surgical Scientific Study or Trial Yes

Department of Defense (DOD) Scientific Study or Trial Yes

AxoGen, Inc. Scientific Study or Trial Yes

Oncovir, Inc - Poly ICLC Scientific Study or Trial Yes

National Institute of Health (NIH/DHHS) Scientific Study or Trial Yes

National Cancer Institute Scientific Study or Trial Yes

National Institute on Drug Abuse Scientific Study or Trial Yes

Kite Pharma Scientific Study or Trial Yes

Lumicell, Inc Scientific Study or Trial Yes

Dendreon Scientific Study or Trial Yes

*PROMAXO: Common Stock Certificate VALUE: 51,205 % SHARE RELATED PARTY: 0.63

- Intuitive no salary/ see referenced COI's
- Promaxo no salary/investment see referenced COI's
- Kite Pharma: Serve as PI. Industry funded for research procedures. Site PI performance no salary
- Poly ICLC: Serve as site PI. Phase I Study of IN SITU Autologous Vaccination Against Prostate Cancer With Intratumoral and Systemic HILTONOL (POLY-ICLC) Prior to Radical Prostatectomy. Product provided free of charge no other funding. -- No salary

*Dr. Ash Tewari (the Principal Investigator in this study and Chairman of Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai) owns equity in the form of stock certificates in Promaxo, for which he serves as an advisor. Promaxo is a privately traded company which develops MRI technology with a focus on prostate cancer.



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.